Xeris Biopharma (XERS) – Investment Analysts’ Recent Ratings Updates

Xeris Biopharma (NASDAQ: XERS) has recently received a number of price target changes and ratings updates:

• 3/7/2025 – Xeris Biopharma had its price target raised by analysts at Leerink Partners from $5.00 to $6.00. They now have an “outperform” rating on the stock.
• 3/7/2025 – Xeris Biopharma had its “neutral” rating reaffirmed by analysts at Piper Sandler. They now have a $4.00 price target on the stock, up previously from $3.00.
• 3/7/2025 – Xeris Biopharma had its price target raised by analysts at Craig Hallum from $5.00 to $6.50. They now have a “buy” rating on the stock.
• 3/7/2025 – Xeris Biopharma had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock, up previously from $6.60.
• 1/29/2025 – Xeris Biopharma had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $6.00 price target on the stock, up previously from $4.00.

Xeris Biopharma Stock Down 1.5 %

Xeris Biopharma stock traded down $0.09 during midday trading on Thursday, reaching $5.43. 2,703,269 shares of the stock traded hands, compared to its average volume of 1,636,737. Xeris Biopharma Holdings, Inc. has a 12 month low of $1.69 and a 12 month high of $5.53. The stock’s fifty day moving average is $3.79 and its 200-day moving average is $3.37. The stock has a market cap of $835.12 million, a P/E ratio of -12.06 and a beta of 2.32.

Institutional Investors Weigh In On Xeris Biopharma

Several large investors have recently bought and sold shares of XERS. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Xeris Biopharma in the 3rd quarter worth $237,000. Intech Investment Management LLC purchased a new position in Xeris Biopharma in the third quarter worth about $130,000. Quantbot Technologies LP bought a new stake in Xeris Biopharma during the third quarter worth approximately $44,000. Walleye Capital LLC bought a new stake in shares of Xeris Biopharma in the 3rd quarter worth about $3,197,000. Finally, Wellington Management Group LLP boosted its holdings in Xeris Biopharma by 11.7% during the 3rd quarter. Wellington Management Group LLP now owns 471,644 shares of the company’s stock valued at $1,344,000 after acquiring an additional 49,535 shares during the period. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.